Bolt Biotherapeutics (BOLT) Depreciation & Amortization (CF) (2020 - 2026)

Bolt Biotherapeutics has reported Depreciation & Amortization (CF) for 7 years, with the latest figure at $203000.0 in Q1 2026.

• Quarterly Depreciation & Amortization (CF) fell 49.12% year-over-year to $203000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.1 million (down 36.41% YoY) and the FY2025 annual result came in at $1.3 million, down 27.51% from the prior year.
• Depreciation & Amortization (CF) eased to $203000.0 in Q1 2026 per BOLT's latest filing, from $255000.0 in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $467000.0 in Q1 2023 and troughed at $203000.0 in Q1 2026.
• A 5-year average of $399705.9 and a median of $439000.0 in 2022 frame the typical range for Depreciation & Amortization (CF).
• The sharpest annual moves came in 2022 and 2026: Depreciation & Amortization (CF) soared 59.38% in 2022, then plunged 49.12% in 2026.
• Over 5 years, Depreciation & Amortization (CF) stood at $462000.0 in 2022, then climbed by 1.08% to $467000.0 in 2023, then decreased by 8.78% to $426000.0 in 2024, then slumped by 40.14% to $255000.0 in 2025, then fell by 20.39% to $203000.0 in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $203000.0, $255000.0, and $290000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.